parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in platelets	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	3 pathways; mostly vesicle traffic	1.00

No case: the score is under the bar. Receipt 17187

STON2 in dopamine neurons, braak-0.18 (p 0.648) → +0.06 (p 0.873)receipt 17196
STON2 in astrocytes, braak+0.00 (p 1.000) → +0.16 (p 0.685)receipt 17195

receipt 17196: STON2 in dopamine neurons, braak

power: full sample -0.04 (p 0.867, n 18), 95% CI -0.50 to +0.43. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.07 (p 0.787, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.03 (p 0.894, n 18). could be the mix.
skeptic: leave-one-out range -0.20 to +0.05, sign flips 3; without severely affected donors -0.04 (p 0.867, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for STON2 in dopamine neurons.

case closed: nothing better to follow up.

receipt 17195: STON2 in astrocytes, braak

power: full sample +0.05 (p 0.840, n 18), 95% CI -0.43 to +0.51. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.07 (p 0.781, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.11 (p 0.658, n 18). could be the mix.
skeptic: leave-one-out range -0.07 to +0.13, sign flips 4; without severely affected donors +0.05 (p 0.840, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for STON2 in astrocytes.

case closed: nothing better to follow up.

loading the receipts